23andMe was once worth $6 billion and is now a penny stock. Layoffs, data breaches, and mass resignations plagued the genomics giant. How did it all unfold?
Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development, backed by strong research and government support.
Inpart’s latest report provides access to the most promising biotech assets and discovery platforms, shedding light on the latest trends in biotech R&D.